MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
1.820
-0.020
-1.09%
After Hours: 1.840 +0.02 +1.09% 18:26 01/17 EST
OPEN
1.870
PREV CLOSE
1.840
HIGH
1.900
LOW
1.785
VOLUME
2.22M
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
1.780
MARKET CAP
381.60M
P/E (TTM)
-1.7327
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALLO last week (0106-0110)?
Weekly Report · 6d ago
Weekly Report: what happened at ALLO last week (1230-0103)?
Weekly Report · 01/06 09:10
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?
Barchart · 01/03 09:17
Weekly Report: what happened at ALLO last week (1223-1227)?
Weekly Report · 12/30/2024 09:09
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 12/26/2024 17:00
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Barchart · 12/26/2024 13:14
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
Barchart · 12/24/2024 07:54
Weekly Report: what happened at ALLO last week (1216-1220)?
Weekly Report · 12/23/2024 09:10
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.